Why Depo-Provera?

Prescribing information and a link to the SPC is available at the bottom of the page.

Depo-Provera is one LARC to consider, whatever her lifestyle – on-the-go, between children, pregnancy scare, forgetful, change in relationship. 

1. Facts to consider

-  Available for over 30 years1
-  Administered every 12 weeks2*† – with a text reminder service (see below for details)
-  Estimated 94% effective with typical use and estimated 99.8% effective with perfect use during the first year of treatment if used consistently and correctly3
-  Intramuscular administration with no specialised training required for healthcare professionals2
-  £6.01 for 12 weeks’ cover4‡

Staying on track with Depo-Provera
Your patients can set a reminder, helping them to remember to book an appointment for their next injection to be given on time. 
How to register for the Depo-Provera text reminder service:
Txt DEPO and the date the injection was given to 83311 in this format DD.MM (e.g. DEPO 31.07)
Three weeks before the next injection is due a reminder text will be sent.  After each injection, your patient will need to re-register for the service.

*Providing the first injection is given during the first five days of a normal menstrual cycle and subsequent injections are given no later than twelve weeks and five days after the previous injection.
Depo-Provera does not protect against sexually transmitted infections (STIs).
Based on cost of one syringe, does not include cost of clinical appointment.

2. Contraindications

There are a few contraindications to be aware of with Depo-Provera.

  1. Hypersensitivity to medroxyprogesterone acetate or to any of excipients listed in section 6.1 of the SPC
  2. Depo-Provera should not be used during pregnancy, either for diagnosis or therapy.
  3. Depo-Provera is contraindicated as a contraceptive at the above dosage in known or suspected hormone-dependent malignancy of breast or genital organs.
  4. Depo-Provera is contraindicated in patients with the presence or history of severe hepatic disease whose liver function tests have not returned to normal.
  5. Whether administered alone or in combination with oestrogen, Depo-Provera should not be employed in patients with abnormal uterine bleeding until a definite diagnosis has been established and the possibility of genital tract malignancy eliminated.

To read the full special warnings and precautions for use for Depo-Provera and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Depo-Provera use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Depo-Provera use should be discontinued.


  1. Pfizer Data on File, 2013.
  2. Depo-Provera Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/11121. Accessed September 2020
  3. Trussell J. Contraceptive failure in the United States. Contraception 2011;(83):397-404.
  4. Pfizer Ltd price list September 2020.

Prescribing Information:

Depo-Provera SPC
Legal Category: POM  Basic NHS Price : £6.01


PP-DEP-GBR-0057.  September 2020